CURRICULUM VITAE

NAME:	Amy Dana Shapiro	
DATE AND PLACE OF BIRTH:	1953; New York United States	
CITIZENSHIP:		
OFFICE ADDRESS:	Indiana Hemophilia and Thrombosis Center, Inc. 8326 Naab Rd. Indianapolis, Indiana 46260	
TELEPHONE:	317 871-0000 (office)	
EDUCATION:	Low-Heywood School Stamford, Connecticut Cum Laude	9/1967 - 6/1971
	Mount Holyoke College South Hadley, Massachusetts	9/1971 -6/1972
	University of Rochester Rochester, New York Degree: 8.S. (Biology/Geology), Cum Laude	9/1972 - 6 1975
	New York University School of Medicine New York, New York Degree: M.D.	9/1976 - 6 1980
POSTGRADUATE TRAINING:	Pediatric Internship and Residency University of Colorado Health Sciences Center Denver, Colorado	6/1980 - 6 1983
	Pediatric Hematology/Oncology Fellowship University of Colorado Health Sciences Center	7/1983 - 6/1987
POSITION:	Medical Director Indiana Hemophilia Comprehensive Center James Whitcomb Riley Hospital for Children Indiana University School of Medicine Indianapolis, Indiana	10/1987 - 6/1998
	Assistant Professor of Pediatrics Indiana University School of Medicine Indianapolis, Indiana	10/1987 - 6/1993
	Associate Professor of Pediatrics Indiana University School of Medicine Indianapolis, Indiana	7/1993 - 6/1998

	Medical Director Indiana Hemophilia and Thrombosis Center Indianapolis, Indiana	7/1998 - present
	Adjunct Professor, Pediatrics Michigan State University East Lansing, Michigan	5/2004 - present
LICENSURE:	State of Colorado	1983
	State of Indiana	1987
BOARD CERTIFICATION:	National Board of Medical Examiners	1980
	American Academy of Pediatrics:	
	Written Boards	1983
	Oral Boards	1986
	American Academy of Pediatrics:	
	Hematology/Oncology	1987
PROFESSIONAL MEMBERSHIPS:	Hemophilia Research Society	1990-present
	International Society on Thrombosis and Hemostasis	1991 -present
	American Society of Hematology	1994 - present
	National Hemophilia Foundation	1995 - present
	World Federation of Haemophilia	1990-present
APPOINTMENTS:	National Hemophilia Foundation	
	Medical & Scientific Advisory Council	1997 -present
	Chair Abstract Review Committee	2000 -present
	Rare Bleeding Disorder Subcommittee Chair	2005 -present
	Advocacy Committee Liaison	2005 -present
	International Network for Pediatric Hemophilia	2006-present
	American Pediatric Society, Society for Pediatric Research	1999 - present
	National Heart Lung and Blood Division of the National Institute of Health, National Data and Safety Monitoring Board for Gene Therapy	2001 -2012
	National Heart Lung and Blood Division of the National Institute of Heath, National Data and Safety Monitoring Board for Transfusion Medicine and Hemostasis	2003 -2014
	National Heart Lung and Blood Division of the National Institute of Health, Clinical Trial Review Committee	2008 -2012
	American Thrombosis and Hemostasis Network: Co-Chairman; Board of Directors	2006 -2013

AWARDS:	Fairfield County Medical Association Award for Excellence in Biological Sciences	6/1970
	Myasthenia Gravis Foundation Medical Student Fellowship Research Grant	1/1973-1/1974
	Tony and Mary Hulman Health Achievement Award	10/1997
	W. George Pinnell Award for Outstanding Service	3/1998
	National Hemophilia Foundation Physician of the Year Award	11/2001
	Distinguished Hoosier Award	08/2009

Publications: Peer and non-peer reviewed

1. Shapiro AD,Jacobson LJ, Armon ME,Manco-Johnson MJ, Hulac P, Lane PA, Hathaway WE: Prevalence of vitamin K deficiency in newborn infants: influence of perinatal risk factors. J Pediatr. 109(4):675-680, 1986.

2. Addiego J, Gomperts E, Gill J, Hilgartner M, Abildgaard C, Parmley R, Shapiro A, Andes A, Krill C, Werner E, Aznar J, Courter S, Kingdon H:Lack of viral transmission in previously untreated hemophiliacs using a monoclonal Ab purified, organic solvent/detergent treated plasma derived factor VIiie concentrate. Transfusion.30(3):284, 1990.

3. Roos KL, Pascuzzi RM, Kuhariak MA, Shapiro AD, Manco-Johnson MJ: Post-partum intracranial venous thrombosis associated with dysfunctional protein C and deficiency of protein S. Obstet and Gynecol. 76(3)2:492-494, 1990.

4. Bottema CDK, Koeberl DD, Ketterling RP, Bowie EJW, Taylor SAM, Lillicrap D, Shapiro AD, Gilchrist G, Sommer SS: A past mutation at isoleucine^{397} is now a common cause of moderate/mild haemophilia B. Br J Haematology. 75(2):212, 1990.

5. Lane PA, Kuypers FA, Clark MR, Andrews DA, Wagner GM, Butikofer P, Shapiro AD, Chiu DTY, Lubin BH, Mentzer WC: Excess of red cell membrane proteins in hereditary high phosphatidylcholine hemolytic anemia. Am J Hematol. 34(3):186-192, 1990.

6. Cooney KA, Nichols WC, Bruck ME, Bahou WF, Shapiro AD, Bowie EJW, Gralnick HR, Ginsburg D: The molecular defect in type IIB von Willebrand disease: Identification of four potential missense mutations within the putative GpIb binding domain.J Clin Invest. 87(4):1227-1233, 1991.

7. Shapiro AD, McKown CG: Oral management of patients with bleeding disorders. Part 1:Medical considerations. J Indiana Dent Assoc. 70(1):28-31, 1991.

8. McKown CG, Shapiro AD: Oral management of patients with bleeding disorders. Part 2:Dental considerations. J Indiana Dent Assoc. 70(2):16-21, 1991.

9. Kenwrick SJ, Levinson B, Metzenberg A, Taylor S, Shapiro A, Gitschier J: Isolation and sequencing of two genes associated with a CpG island 5' of the factor VIII gene. Human Molecular Genetics. 1(3):179-186, 1992.

10. Fay WP, Shapiro AD, Shh JL. Schleef RR, Ginsburg D: Brief report: complete deficiency of plasminogen activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med. 327(24):1729 1733, 1992.

11. Shapiro AD, Clarke SL, Christian JM, Odom LF, Hathaway WE: Thrombosis in children receiving L-asparaginase; Determining a group at risk. Am J Pediatr Hematol Oncol. 15(4):400 405, 1993.

12. Bottema CDK, Ketterling RP, Vielhaber E, Yoon HS, Gostout B, Jacobsen DP, Shapiro A, Sommer SS: The pattern of spontaneous germ-line mutation: relative rates of mutation at or near CpG dinucleotides in the factor IX gene. Human Genetics. 91:496 503, 1993.

13. Fay WP, Eitzman OT, Shapiro AD, Madison EL, Ginsburg D: Platelets inhibit fibrinolysis by both plasminogen activator inhibitor-1 dependent and independent mechanisms. Blood. 83(2):351 356, 1994.

14. Bray GL, Gomperts ED, Courter S, Gruppo R, Gordon EM, Manco-Johnson M, Shapiro A, Scheibe! E, White G, Lee M, and the Recombinate Study Group: A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. Blood. 83(9)2428-2435, 1994.

15. Gertner JM, Kaufman FR, Danfield SM, Sleeper LA, Shapiro AD, Howard C, Gomperts ED, Hilgartner MW: Delayed somatic growth and pubertal development in hemophiliac boys: The Hemophilia Growth and Development Study. J Pediatr. 124(6)896-902, 1994.

16. Shapiro A. Long-term surveillance of HIV, HBV, and HCV infected patients. Ann Hematol. 68(3)87-88, 1994.

17. Tanimura LK, Weddell JA, McKown CG, Shapiro AD, Mulherin J: Oral management of a patient with a plasminogen activator inhibitor (PAI 1) deficiency: case report. Pediatr Dentistry. 16(2):133-135, 1994.

18. Shapiro AD: Hemorrhagic diatheses associated with cyanotic congenital heart disease. International J Pediatr Hematol Oncol. 16(1)139-145, 1994.

19. Shapiro AD: New factor IX concentrates. International J Pediatr Hematol. 16(1)479-490, 1994.

20. Shapiro A, Abe T, Aledort LM, Anderle K, Hilgartner MW, Kunschak M, Preston FE, Rtvard GE, Schimpf K, and the International Factor Safety Study Group: Low risk of viral infection after administration of vapor-heated factor VII or factor IX complex in first-time recipients of blood components. Transfusion. 35(3)204-2088, 1995.

21. Warrier I, Kasper CK, White GC, Shapiro AD, Bergman GE, and the Mononine Study Group: Safety of high doses of a monoclonal antibody-purified factor IX concentrate. Am J Hematology. 49(1):92 94, 1995.

22. White GC, Shapiro AD, Kurczynskj E, Kim HC, Bergman GE, and the Mononine Study Group: Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia 8. Thromb Haemost. 73(5):779-84, 1995.

23. Shapiro, A: Antithrombin deficiency in special clinical syndromes • part 1: neonatal and pediatric/ physiologic deficiency: extracorporeat membrane oxygenation. Seminars in Hematology. 32(4);2:33 36, 1995.

24. Shapiro AD, Ragni MV, Lusher JM. Culbert S, Koerper MA, Bergman GE, Hannan MM: Safety and efficacy of monoclonal antibody-purified factor IX concentrate in previously untreated patients with hemophilfa B. Thromb Haemost. 75(1)30 35, 1996.

25. Shapiro AD: American experience with home use of NovoSeven®: Recombinant factor VIia In hemophiliacs with inhibitors. Haemostasis. 26(1):143-149, 1996.

10(5):428-437, 2004.

55. Ewenstein 8, Valentino L, Journeycake J, Tarantino M, Shapiro A, Blanchette V, Hoots W, Buchanan G, Manco-Johnson M, Rivard G, Miller K, Geraghty S, Maahs J, Stuart R, Dunham T, Navickis R. Consensus recommendations for use of central venous access devices in haemophilia. Haemophilia. 10(5):629-648, 2004.

56. Shapiro AD. Review: Continuous infusion and inhibitor development in mild hemophilia A: cause or bystander? International Monitor: Reviews of current key literature on Hemophilia. 12(1): 29-30, 2004.

57. Shapiro A, DiPaola J, Cohen A, Pasi J, Heisel M, Blanchette V, Abshire T, Hoots K, Lushcer J, Negrier C, Rothschild C, Roth D. The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia 8. Blood. 105:518-525, 2005

58. Parameswaran R, Shapiro A, Gill J, Kessler C, HTRS Registry Investigators. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia. 11(2):100-6, 2005.

59. Kessler CM, Gill JC, White GC, Shapiro A, Arkin S, Roth DA, Meng X, Lusher JM. B-Domain Deleted Recombinant Factor VIII Preparations are Bioequivalent to a Monoclonal Antibody Purified Plasma-Derived Factor VIII Concentrate: A Randomized, Three-Way Crossover Study. Haemophilia. 11(2):84-91, 2005.

60. Pratt EL, Tarantino MD, Wagner D, Pescovitz OH, Bowyer S, Shapiro AD. Prevalence of Elevated Antithyroid Antibodies and Antinuclear Antibodies in Children with Immune Thrombocytopenic Purpura. Am J Hematol. 79(3):175-9, 2005.

61. Berntorp E, Astermark J, Danfield S, Nelson G, Oldenburg J, Shapiro A, DiMichele D, Ewenstein 8, Gomperts E, Winkler C, for the Hemophilia Inhibitor Genetics Study. Hemophilia Inhibitor Genetics Study (HIGS) – evaluation of a model for studies of complex diseases using linkage and association methods. Haemophilia. 11(4):427-429, 2005.

62. Danfield SM, Shapiro AD Gomperts ED, Lynn H. Hemophilia-related Morbidity and Quality-of-Life. Haemophilia. 11(4):418, 2005.

63. Shapiro A, Korth-Bradley J, Poon MC. Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia. Haemophilia. 11(6):571-82, 2005.

64. Shapiro AD. Review: Of mice and men: a murine model of hemophilia synovitis. International Monitor: Reviews of current key literature on Hemophilia. 13(2):40-41, 2005.

65. Berntorp E, Shapiro A, Astermark J, Blanchette V, Collins P, DiMichele 0, Escuriola C, Hay C, Hoots WK, Lessinger C, Negrier C, Oldenburg J, Peerlinck K, Reding M, Hart C. Inhibitor treatment in haemophilias A and B: Summary statement for the 2006 international consensus conference. Haemophilia. 12(6):1-7, 2006.

66. Mehta A, Parameswaran R, Shapiro A. An overview of history, clinical practice concerns, comparative studies and strategies to optimize therapy of bypassing agents. Haemophilia. 12(6):1-8, 2006

67. Shapiro AD. Review: Immune tolerance induction: in search of the silver bullet. International Monitor: Reviews of current key literature on Hemophilia. 14(2):30-31, 2006.

68. Shapiro AD. Review: Cost and outcome of hemophilia therapy. International Monitor: Reviews of current key literature on Hemophilia. 14(2): 41-2, 2006.

69. Shapiro AD. A short measure of health-related, disease-specific quality of life. International Monitor on Hemophilia. 15(1): 40-1,2007.

70. Hacker M, Page J, Shapiro A, Rich-Edwards J, Manco-Johnson M. Central Venous Access Device Infections in Children with Hemophilia – A Comparison of Prophylaxis and Episodic Therapy. Pedatr Hematol Oneal. 29(7):458-464, 2007.

71. Tencer T, Roberson C, Duncan N, Johnson K, Shapiro A. A Haemophilia Treatment Center administered disease management programme in patients with bleeding disorders. Haemophilia. 13(5):480-8, 2007.

72. Shapiro AD. Anti-hemophilic Factor (Recombinant),Plasma/Albumin-Free Method (octocog alpha; ADVATE ®) in the Management of Hemophilia A. Review. Vascular Health and Risk Management. 3(5)555-65, 2007.

73. Manco-Johnson M, Abshire T, Shapiro A, Riske 8, Hacker M, Kilcoyne R, Ingram 0, Manco-Johnson M, Funk S, Jacobson L, Valen•ino L, Hoots WK, Buchanan G, DiMichele D, Recht M, Brown 0, Leisinger C. Bleak S, Cohen A, Mathew P, Matsunaga A, Medeiros 0, Nugent 0, Thomas G, Thompson A, Soucie JM, Austin H, Evatt B. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med.9;357(6):535-44,2007.

74. Mehta R, Shapiro AD. Therapeutic Options for Ligneous ConjunctMtis. Haemostasis Forum [online). Posted November 20, 2007. Avallabfe at:http://www.haemostasis-forum.org/.

75. Shapiro AD. Review:NovoSeven® for surgicalcoverage h hemophilic patients with inhibitors. International Monitor: Reviews of current key literature on Hemophilia.16(1)26-7, 2007.

76. Sharathkumar A, Greist A, DiPaola J, Winay J, Roberson C, He.iman S, Herbert S, Parameswaran R, Shapiro A. Bidogic response to subcutaneous and intranasal therapy wtth desmopressin (DDAVP) in a large Amish kindred with Type 2M Von Willebrand Disease (VWD). Haemophilia. 14(3)539-48, 2008.

77. Negrier C, Shapiro A, Berntorp E, Pabinger I, Tarantino M, Retzios A. Surgical evaluation of a recombinant Factor VHI prepared using a plasma/albumin-free method: Efficacy and Safety of Advate in previously treated patients. Thromb Haemost. 100(2)217-23,2008.

78. Shapiro AD. Single-dose Recombinant Activated Factor VII for the treatment of Joint Bleeds in Hemophilia Patients with Inhibitors. Clin Adv Hernatol Oneal. 6(8):579-86, 2008.

79. Blanchette VS, Shapiro AD, Liesner RJ, Hernandez Navarro F, Warrier I, Retzios AD, Schroth PC, Spotts G, Ewenstein BM, for the rAHF-PFM ClinicalStudy Group. Plasma and Albumin Free Recombinant Factor VIII (rAHF-PFM): Pharmacokinetics, Efficacy and Safety in Previously Treated Pedatric Patients. J Thromb Haemost. 8;6(8):1319-26, 2008.

80. Mehta R, Shapiro, AD. Plasminogen deficiency. Haemophilia. 14(6):1261-68, 2008.

81. Mehta R, Shapiro, AD. Plasminogen activator inhibitor Type Ideficiency. Haemophilia. 14(6):1255-60, 2008.

82. Sharathkumar A, Shapiro AD. Hereditary Hemorrhagic Telangectasia. Haemophilia. 14(6):1269-80, 2008.

83. Sharathkumar A, Kerlin B, Greist A, Hardesty B, Sulkin M, Heiman M, Salter J, Shapiro A. Variability in Bleeding Phenotype in Amish Carriers of hemophilia B with the 31008 CT mutation. Haemophilia. 15(1):91-100, 2009.

84. Shapiro A, Gruppo R, Pabinger I, Collins PW, Hay CR, Schroth P, Casey K, Patrone L, Ehrlich H, Ewenstein

BM. Integrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia A. Expert Opin Biol Ther. 9(3):273-83, 2009.

BS. Collins PW, Blanchette VS, Fischer K, Bjorkman S, Oh M, Fritsch S. Schoth P, Spotts G, Astermark J, Ewenstein; rAHF-PFM Study Group. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost. 7(3):413-20, 2009.

86. Bernardi F, Dolce A, Pinotti M, Shapiro AD, Santagostino E, Peyvandi F, Batorova A, Lapecorella M, Schved JF, Ingerslev J, Mariani G. Major differences in bleeding symptoms between factor VII deficiency and hemophilia B. J Thromb Haemost. 7(5):774-9, 2009.

67. Valentino L, Recht M, DiPaola J, Shapiro A, Pipe S, Ewing N, Urgo J, Bullock T, Simmons M, DeGuzman C. Experience with a Third Generation Recombinant Factor VIII Concentrate (Advate) for Immune Tolerance Induction in Patients with Haemophilia A. Haemophilia. 15(3):71B-26, 2009.

88. Sharathkumar AA, Lemear N, Pipe S, Parikh S, Russell M, Simon A, Shapiro, A. Management of neonatal aortic arch thrombosis with low-molecular weight heparin: a case series. J Pediatr Hematol Oncol. 31(7):516-21, 2009.

89. Metjian AD, Wang C, Sood SL, Cuker A, Peterson SM, Soucie JM, Konkle BA; HTCN Study Investigators. Bleeding symptoms and laboratory correlation in patients with severe von Willebrand disease. Haemophilia. 15(4):918-25, 2009.

90. Ferrarini A, Ramelli GP, Bianchetti MG, Hedman J, Sharathkumar A, Shapiro A, Bourland C. A Child with Epistaxis. Case Report; Index of Suspicion. Pediatrics in Review. Pediatr Rev. 30(12):479-85, 2009.

91. Kulkarni R, Soucie JM, Lusher J, Presley R, Shapiro A, Gill J, Manco-Johnson M, Koerper M, Mathew P, Abshire T, DiMichele D, Hoots K, Janco R, Nugent D, Geraghty S, Evatt B; the Haemophilia Treatment Center Network Investigators. Sites of initial bleeding episodes, mode of delivery and age of diagnosis in babies with haemophilia diagnosed before the age of 2 years: a report from The Centers for Disease Control and Prevention's (CDC) Universal Data Collection (UDC) project. Haemophilia. 15(6):1281-90, 2009.

92. Duncan NA, Kronenberger WG, Roberson, CP, Shapiro AD. VERITAS-PRN: a new measure of adherence to episodic treatment regimens in haemophilia. Haemophilia. 16(1):47-53, 2010.

93. Duncan NA, Kronenberger W, Roberson C, Shapiro A. VERITAS-Pro: a new measure of adherence to prophylactic regimens in haemophilia. Haemophilia. 16(2):247-55, 2010.

94. Flood V, Gill J, Morateck P, Christopherson P, Friedman K, Haberichter S, Branchford B, Hoffmann R, Abshire T, Di Paola J, Hoots WK, Leissinger C, Lusher J, Ragni M, Shapiro AD, Montgomery R. Common VWF exon 28 polymorphisms associated with decreased VWF:RCoNWFAg ratios. Blood. 15:116(2):280-6, 2010.

95. Bjorkman S, Blanchette VS, Fischer K, Oh M, Spotts G, Schroth P, Fritsch S, Patrone L, Ewenstein BM, Advate Clinical Group, Collins PW. Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring. J Thromb Haemost. B(4):730-6, 2010.

96. Sharathkumar AA, Soucie JM, Trawinski B, Greist A, Shapiro AO. Prevalence and risk factors of cardiovascular disease (CVD) events among patients with hemophilia: experience of a single hemophilia treatment center in the United States (US). Haemophilia. 17(4):597-604, 2011.

97. Zhou ZY, Wu J, Baker J, Curtis R, Forsberg A, Huszti H, Koerper M, Lou M, Miller R, Parish K, Riske B, Shapiro A, Ullman M, Johnson K. Haemophilia utilization group study - Part Va (HUGS Va): design,

methods and baseline data. Haemophilia. 17(5):729-36, 2011.

98. Gill J, Shapiro AD, Valentino L, Bernstein J, Friedman C, Nichols W, Manco-Johnson M. von Willebrand factor/factor VIII concentrate (Humate-P) for management of elective surgery in adults and children with von Willebrand disease. Haemophilia. 17(6):895-905, 2011.

99. Shapiro AD, Soucie JM, Peyvandi F, Aschman DJ, DiMichele DM. Knowledge and therapeutic gaps: a public health problem in the rare coagulation disorders population. Am J Prev Med. 41(6 Suppl 4):S324-31, 2011.

100. Aschman DJ, Abshire TC, Shapiro AD, Lusher JM, Forsberg AD, Kulkarni R. A community-based partnership to promote information infrastructure for bleeding disorders. Am J Prev Med. 41(6 Suppl 4):S332-7, 2011.

101. Shapiro AD, Hedner U. Advances in Bypassing Agent Therapy for Hemophilia Patients With Inhibitors to Close Care Gaps and Improve Outcomes. Therapeutic Advances in Drug Satety. 2(5):213-225, 2011.

102. Shapiro AD, Pipe S, Geraghty S, Pezalla E, Jorgenson JA, Tadlock C, Wulff K, Kaminsky R, Kessler C. Hemophilia and Managed Care: Partnering to Achieve Cost-Effective Care. The American Journal of Pharmacy Benefits. 3(5):248-55, 2011.

103. Young G, Shapiro AD, Walsh CE, Gruppo RA, Gut RZ, Cooper DL. Patient/Caregiver-reported recombinant factor VIIa (rFVIIa) dosing: home treatment of acute bleeds in the Dosing Observational Study in Hemophilia (DOSE). Haemophilia. 18(3) 392-9, 2012.

104. Bemtorp E, Shapiro AD. Modern Hemophilia Care. The Lancet. 379(9824): 1447-56, 2012.

105. Shapiro AD, Ragni MV, Valentino LA, Key NS, Josephson NC, Powell JS, Cheng G, Thompson AR, Goyal J, Tubridy KL, Peters RT, Dumont JA, Euwart D, Li L, Hallen B, Gozzi P, Bitonti AJ, Jiang H, Luk A, Pierce GF. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood. 119(3):666-72, 2012.

106. Bellissimo DB, Christopherson PA, Flood VH, Gill JC, Friedman KD, Haberichter SL, Shapiro AD, Abshire TC, Leissinger C, Hoots WK, Lusher JM, Ragni MV, Montgomery RR. VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population. Blood. 119(9):2135-40, 2012.

107. Bemtorp E; Shapiro A; Waters J; Astermark J. The International Factor IX Treatment Network Survey. Haemophilia. 18(3):e60-e62, 2012.

108. Duncan N, Shapiro A, Ye X, Epstein J, Luo MP. Treatment patterns, health-related quality of life and adherence to prophylaxis among haemophilia A patients in the United States. Haemophilia. 18(5):760-5, 2012.

109. Shapiro AD, Cooper D. US Survey of Surgical capabilities and experience with surgical procedures in patients with congental haemophilia with inhibitors. Haemophilia. 18(3):400-5, 2012.

110. Escobar M, Maahs J, Hellman E, Donkin J, Forsyth A, Hroma N, Young G, Valentino LA, Tachdjian R, Cooper DL, Shapiro AD. Multidisciplinary management of patients with haemophilia with inhibitors undergoing surgery in the United States: perspectives and best practices derived from experienced treatment centres. Haemophilia. 18(6):971-81, 2012.

111. Martinowitz U, Shapiro A, Quon DV, Escobar M, Kempton C, Collins PW, Chowdary P, Makris M, Mannucci PM, Martini M, Valentino LA, Gomperts E, Lee M. Pharmacokinetic properties of 161001, an investigational

recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis. Haemophilia. 18(6):881-7, 2012.

112. Astermark J, Donfield SM, Gomperts ED, Schwarz JA, Menius ED, Pavlova A, Oldenburg J, Kessing B, DiMichele OM, Shapiro AD, Winkler CA, Berntorp E. The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. Blood. 121(8):1446-54, 2013.

113. Flood VH, Friedman KO, Gill JC, Haberichter SL, Christopherson PA, Branchford BR, Hoffmann AG, Abshire TC, Dunn AL, Di Paola JA, Hoots WK, Brown DL, Leissinger C, Lusher JM, Ragni MV, Shapiro AD, Montgomery RR. No increase in bleeding identified in type 1 VWD subjects with 01472H sequence variation. Blood. 121(18):3742-4, 2013.

114. Schwarz J, Astermark J, Menius ED, Carrington M, Oonfield SM, Gomperts ED, Nelson GW, Oldenburg J, Pavlova A, Shapiro AD, Winkler CA, Berntorp E. *F8* Haplotype and Inhibitor Risk: Results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. Haemophilia. 19(1):113-8, 2013.

115. Miller CH, Rice AS, Boylan B, Shapiro AD, Lentz SR, Wicklund BM, Kelly FM, Soucie JM, The Hemophilia Inhibitor Research Study Investigators. Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII in the US Hemophilia Inhibitor Research Study. J Thromb Haemost. 11:1300-9. 2013.

116. Larsen OM, Haberichter SL, Gill JC, Shapiro AD, Flood VH. Variability in platelet- and collagen-binding defects in type 2M von Willebrand disease. Haemophilia. 19(4):590-4, 2013.

117. Rampersad AG, Shapiro AD, Rodriguez-Merchan EC, Maahs JA, Akins S, Jimenez-Yuste V. Radiosynovectomy: review of the literature and report from two haemophilia treatment centers. Blood Coagul Fibrinolysis. 24(5):465-70, 2013.

118. Mannucci PM, Kempton C, Millar C, Romond E, Shapiro A, Birschmann I, Ragni MV, Gill JC, Yee TT, Klamroth R, Wong WY, Chapman M, Engl W, Turecek PL, Suiter TM, Ewenstein BM. Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial. Blood. 122:648-57. 2013.

119. Shapiro A. Development of long-acting recombinant FVIII and FIX Fe fusion proteins for the management of hemophilia. Expert Opin Biol Ther. 13(9):1287-97. 2013.

120. Lane J, Mclaren PJ, Dorrell L, Shianna KV, Stemke A, Shapiro A, et all. A genome-wide association study of resistance to HIV infection in highly exposed uninfected individuals with hemophilia A. Hum Mol Genet. 22(9):1903-10. 2013.

121. Hinckley JO, Abbott 0, Burns TL, Heiman M, Shapiro AD, Wang K, DiPaola J. Quantitative trait locus linkage analysis in a large Amish pedigree identifies novel candidate loci for erythrocyte traits. Molecular Genetics & Genomic Medicine 1(30):131-41. 2013.

122. Shapiro AD. Long-lasting recombinant factor VIII proteins for hemophilia A. Hematology Am Soc Hematology Education Program. 2013:37-43. 2013.

123. Soucie JM, Miller CH, Kelly FM, Payne AB, Creary M, Bockenstedt PL, Kempton CL, Manco-Johnson MJ, Neff AT; the Haemophilia Inhibitor Research Study Investigators. A study of prospective surveillance for inhibitors among persons with haemophilia in the United States. Haemophilia. 20(2):230-7. 2014.

124. Shapiro AD, Neufeld EJ, Blanchette V, Salaj P, Gut AZ, Cooper DL. Safety of recombinant activated factor

VU (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 µg kg-1) rFVIIa doses across clinical trials and registries. Haemophilia. 20(1):e23-31. 2014.

125. Heiman M, Gupta S, Shapiro AD. The obstetric, gynaecological and fertility implications of homozygous PAI 1 deficiency: single-centre experience. Haemophilia. 20(3):407-12. 2014.

126. Mahlangu J, Powell JS, Ragni MV, Chowdary P, Josephson NC, Pabinger I, Hanabusa H, Gupta N, Kulkarni R, Fogarty P, Perry D, Shapiro A, et al. Phase 3 study of recombinant factor VIII Fe fusion protein in severe hemophilia A. Blood. 123(3):317-25. 2014.

127. Duncan N, Roberson C, Lail A, Danfield S, Shapiro A. A haemophilia disease management programme targeting cost and utilization of specialty pharmaceuticals. Haemophilia. 20(4):519-26. 2014.

128. Lock J, Raat H, Duncan N, Shapiro A, Bijlevelt M, Peters M, Tamminga RY, Leebeek FW, Moll HA, Cnossen MH. Adherence to treatment in a Western European paediatric population with haemophilia: reliability and validity of the VERITAS-Pro scale. i. Haemophilia. 20(5):616-23. 2014.

129. Shapiro AD, Akins S, Cooper DL. Long-term outcomes from orthopaedic surgery in haemophilia: are we measuring success and documenting and assessing complications? Haemophilia. 20(5) e367-71. 2014.

130. Rampersad A, Hampton K, Duncan N, Roberson C, Slayten J, Davisson S, Aronowtz J, Shapiro A. Noninvasive buccal swab antigen sample and molecular testing provides extended antigen typing for patients with hemoglobinopathies. Journal of Pediatrics. 165(5):1003-7. 2014.

131. Shapiro AD, Ragni MV, Kulkarni R, Oldenberg J, Srivastava A, Quon DV, Pasi KJ, Hanabusa H, Pabinger I, Mahlangu J, Fogarty P, Lillicrap D, Kulke S, Potts J, Neelakantan S, Nestorov I, Li S, Dumont JA, Jiang H, Brennan A, Pierce GF. Recombinant factor VIII Fe fusion protein: Extended-interval dosing maintains low bleeding rates and correlates with von Willebrand Factor levels. J Thromb Haemost. 12(11):1788-800. 2014.

132. Berntorp E, Shapiro AD, Waters J, Astermark J. A comparison of the treatment of patients with factor IX deficiency to that of those with factor VIII deficiency: results of an International Survey conducted as part of the International FIX Treatment Network. Haemophilia. 20(5):e362-4. 2014.

133. Powell J, Shapiro AD, Ragni M, Negrier C, Windyga J et al. Switching to recombinant factor IX Fe fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates. Br J Haematol. 168(1):113-23. 2015.

134. Nakar C, Manco-Johnson M, Lail A, Danfield S, Maahs J, Chong Y, Blades T, Shapiro A. Prompt Immune Tolerance Induction at Inhibitor Diagnosis Regardless of Titer May Increase Overall Success in Hemophilia A Complicated by Inhibitors: Experience of Two US Centers. Haemophilia. 21(3):365-73 2015.

135. Duncan NA, Roberson CP, Shapiro AD. Comment on: Khair K. Compliance, concordance and adherence: what are we talking about? Haemophilia Sept 2014;20(5):601-3. Haemophilia. May;21(3):e235-6. 2015.

136. Palla R, Peyvandi F, Shapiro AD. Rare bleeding disorders: diagnosis and treatment. Blood. Mar 26;125(13):2052-61. 2015.

137. Kruse Jarres R, St-Louis J, Greist A, Shapiro A, Smith H, Chowdary P, Drebes A, Gomperts E, Bourgeois C, Mo M, Novack A, Farin H, Ewenstein B. Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A. Haemophilia. Mar;21(2):162-70. 2015.

138. Shapiro AD, Schoenig-Diesing C, Svati-Fidell L, Wong WY, Romanov V. Integrated analysis of safety data from 12 clinical interventionalstudies of plasma- and albumin-free recombinant factor VIII (rAHF-PFM) in haemophilia A. Haemophilia. Nov;21(6):791-8.2015.

139. Shapiro AD, Li S. Response to Gringeri et al.:'recombinant full-length factor VIII (FVIII) and extended half-life FVIII products in prophylaxis - new insight provided by pharmacokinetic modelling'. Haemophilia. Nov;21(6):e489-92.2015.

140. Flood VH, Christopherson PA, Gill JC, Friedman KD, Haberichter SL, Bellissimo DB, Udani RA, Dasgupta M, Hoffmann RG, Ragni MV, Shapiro AD, et al. Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States. Blood. 19;127(20):2481-8. 2016.

141. Austin SK, Kavakli K, Norton M, Peyvandi F, Shapiro A; FX Investigators Group. Efficacy, safety and pharmacokinetics of a new high-purity factor X concentrate in subjects with hereditary factor X deficiency. Haemophilia. May;22(3):419-25. 2016.

142. Austin SK, Brindley C, Kavakli K, Norton M, Shapiro A; FX Investigators Group. Pharmacokinetics of a high-purity plasma-derived factor X concentrate in subjects with moderate or severe hereditary factor X deficiency. Haemophilia. May;22(3):426-32. 2016.

143. Duncan NA, Kronenberger WG, Hampton KC, Bloom EM, Rampersad AG, Roberson CP, Shapiro AD. A validated measure of adherence to antibiotic prophylaxis in children with sickle cell disease. Patient Prefer Adherence. Jun 8;10:983-92. 2016.

144. Manco-Johnson MJ, Bomgaars L, Palascak J, Shapiro A, Geil J, et al. Efficacy and safety of protein C concentrate to treat purpura fulminans and thromboembolic events in severe congenital protein C deficiency. Thromb Haemost. Jul 4; 116(1):58-68. 2016.

145. Croteau SE, Nakar C, Neufeld EJ, Shapiro A, Cooper DL. Safety and efficacy of recombinant factor VIIa by pediatric age cohort: reassessment of compassionate use and trialdata supporting US label. Pediatr Blood Cancer. Oct;63(10):1822-8. 2016.

146. Gupta S, Heiman M, Duncan N, Hinckley J, DiPaola J, Shapiro AD. Variable bleeding phenotype in an Amish pedigree with von Willebrand disease. Am J Hematol. Oct;91(10):E431-5. 2016.

147. Sood SL, James AH, Ragni MV, Shapiro AD, Witmer C, Vega R, Bolgiano D, Konkle BA. A prospective study of von Willebrand factor levels and bleeding in pregnant women with type 1 van Willebrand disease. Haemophilia. Nov;22{6):e562-e564. 2017.

148. Shapiro, A. Plasma-derived human factor X concentrate for on-demand and perioperative treatment in factor X-deficient patients: pharmacology, pharmacokinetics, efficacy, and safety. Expert Opin Drug Metab Toxicol. Nov 2:1-8. 2016. [Epub ahead of print).

149. Afzal MZ, Gartz M, Klyachko EA, Khan SS, Shah SJ, Gupta S, Shapiro AD, et al. Generation of human iPSCs from urine derived cells of patient with a novel heterozygous PAI-1 mutation. Stem Cell Res. Jan;18:41-44. 2017.

150. Afzal MZ, Gartz M, Klyachko EA, Khan SS, Shah SJ, Gupta S, Shapiro AD, Vaughan DE, Strande JL. Generation of human iPSCs from urine derived cells of a non-affected control subject. Stem Cell Res. Jan;18:33-36. 2017.

151. Shapiro, A. Plasma-derived human factor X concentrate for on-demand and perioperative treatment in factor X-deficient patients: pharmacology, pharmacoklnetics, efficacy, and safety. Expert Opin Drug Metab Toxlcol. Jan; 13(1):97-104. 2017.

152. Pasi KJ, Fischer K, Ragni M, Nolan B, Perry DJ, Kulkarni R, Ozelo M, Mahlangu J, Shapiro AD, et.al. Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fe fusion proteim (rFIXFc) in subjects with haemophlia B. Thromb Haemost. Feb. 26; 117(3):508-516. 2017.

153. Quon DV, Klamroth R, Kulkarni R, Shapiro AD, et.al. Low bleeding rates with increase or maintenance of physical activity in patients treated with recombinant factor VIII Fe fusion protein (rFVlllFc) in the A-LONG and Kids A-LONG Studies. Haemophilia. Jan; 23(1):e39-e42. 2017.

154. Kukarni R, Presley RJ, Lusher JM, Shapiro AD, et al. Complications of haemophilia in babies (first two years of life): a report from the Centers for Disease Control and Prevention Universal Data Collection System. Haemophilia. Mar; 23(2):207-214. 2017.

155. Shapiro AD, Mahlangu JN, Perry D, Pasi J, Quon DV, Chowdary P, Tsao E, Li S, Innes A, Pierce GF, Allen GA. Treatment of bleeding episodes with recombinant factor Viti Fe fusion protein in A-Long study subjects with severe haemophilia A. Haemophilia. Feb. 20. 2017 [Epub ahead of print}.

Abstracts

1. Shapiro AD, Hulac P, Jacobson LJ, Lane PA. Manco-Johnson MJ, Hathaway WE: Prevalence of vitamin K deficiency in newborn infants: influence of perinatal risk factors. Thromb Haemost. 54:125;0738a, 1985.

2. Hulac P, Shapiro AD, Manco-Johnson MJ, Jacobson L, Hathaway WE: Maternal anti-convutsants and neonatal vitamin K deficiency. Pediatr Res. 20(4):390, 1377a, 1986.

3. Shapiro AD, Clarke SL, Christian MJ, Hays T, Odom LF, Hathaway WE: Thrombosis in patients feceiving L-asparaginase: Determining an at-risk group. Peidtr Res. 20(4) 287;789a, 1986.

4. Lane P, Kuypers F, Wagner G, Butikofer P, Shapiro A, Chiu 0, Lubin B, Clark M, Mentzer W: Characterization of high Na+ bw K+ red blood cells (ABC) in a family with hereditary high phosphatidylcholine (PC) hemotytic anemia. Blood. 68(1):101,56a, 1966.

5. Kingdon HS, Gomperts E, Addego J, Gill J, Hifgartner M, Abildgaard C, Parmley R, Shapiro A, Andes A, Krill C, Anzar J: Clinical evaluation of the viral safety of a monoclonal Ab purified, organic solvent/detergent treated plasma derived factor Vliie concentrate. Blood. 72(1):300a, 1988.

6. Cooney KA, Nichols WC, Bruck ME, Bowie EJW, Shapiro A, Gralnick HR, Ginsburg D: The molecular defect in type JIB von WiJlebrand disease (vWD): identification of two potential missense mutations within the putative GPlb binding domain. Blood. 76(10)1166a, 1990.

7. Kenwrick S, Metzenberg A, Klapholz S, Shapiro A, Gamel P, Gitschier J: Isolation of CpG islands and associated transcripts near the human factor VIII gene. Am J of Human Genetics. 47223a, 1990.

8. Fay W, Shapiro A, Shih J, Schleef R, Ginsburg 0; Identification of a molecular defect in plasminogen activator inhibitor-1 (PAI-1) deficiency: implications for PAI-1 function in vivo. Blood. 78(1)30178a; 1991.

9. Fay WP, Shapiro AD, Shih JI, Schleef RR, Ginsburg D: Human plasminagen activator inhibitor-1 deficency. Circulation. 86(4)4:1-L, 0596a 32-33, 1992.

10. Rupp TH, Clark OW, Shapiro A, Harris S, Greist A, Lee CH, Lumeng L: Sensitivity and specificity of anti-HCV EIA in hemophiliacs. Gastroenterology. 102(4)877a, 1992.

11. Shapiro A and the International Factor Safety Study Group: A study to determine safety of virus inactivated factor concentrates in hemophiliacs naive to blood product administration - factor VIII concentrate (human) Immune, vapor heated and factor IX complex (human) Immuno, vapor heated. XX International Congress of the World Federation of Hemophilia. 45a, 1992.

12. Shapiro A and the International Factor Safety Group: Vapor heated intermediate-purity factor IX concentrate tested in a safety study monitoring transfusion- related viral infection in previously untreated hemophiliacs. Thromb Haemost, 69(6):1453a, 1993.

13. Shapiro A, Bergman GE, and the Mononine Study Group: Monoclonal antibody purified factor IX: viral safety in PUPs. Blood. B2(10);1:243a, 1993.

14. Kisker CT, Sleeper L, Hoots WK, Evatt B, Drake J, Davignon G, Shapiro A: Effects of boosting and *AZT* treatment on MMR titers in HIV+ children with hemophilia. Blood. 82(10);1:1642a, 1993.

15. Kurczynski E, Lusher JM, Pitel P, Shapiro A. Bergman GE, and the Mononine Study Group: Safety and efficacy of monoclonal antibody purified factor IX concentrate for management of spontaneous or traurna-induced bleeding and surgical prophylaxis in previously treated pediatric patients with hemophilia B. XXI International Congress of the World Federation of Hemophilia. 273, 1994.

16. White GC, Shapiro A, Pitel P, Bergman GE, and the Mononine Study Group: Safety and efficacy of monoclonal antibody in hemophilia B patients undergoing surgical procedures. XXI International Congress of the World Federation of Hemophilia. 111, 1994.

17. White GC, Shapiro A, Pitel P, Bergman GE, and the Mononine Study Group: Safety and efficacy of monoclonal antibody purified factor IX concentrate in hemophilia B patients undergoing surgical procedures. XXI International Congress of the World Federation of Hemophilia. 112, 1994.

18. Warrier I, Kasper CK, White GC, Shapiro A, Bergman GE, and the Mononine Study Group: Safety of high doses of a monoclonal antibody purified factor IX concentrate. XXI International Congress of the World Federation of Hemophilia. 112, 1994.

19. Hilgartner M, Evatt B, Maeder M, Drake J, Hawk S, Hoots WK, Jason J, Kalish L, Pattishall E, Shapiro A, Warrier I: Vaccination practices and response to boosting among children and adolescents enrolled in the Hemophilia Growth and Development Study (HGDS). Pediatr Research. 35(4);2:954a, 1994.

20. White G, Shapiro A, Ragni M, Kaye J, Tubridy K, McCarthy K, Courter S: Phase I/II pharmacokinetics, safety and efficacy data of recombinant human factor IX in previously treated patients with hemophilia B. Blood. 06(10)1:761a, 1995.

21. Ragni M, Shapiro A, White G, Beebe A, Gencarella N, Doherty K: Use of recombinant factor IX in three patients with hemophilia B undergoing surgery. Blood. 86(10);1:762a, 1995.

22. Fay WP, Shapiro AD: Analysis of a large pedigree with plasminogen activator inhibitor-1 deficiency. Circulation. 94:1-460a, 1996.

23. Greist A, Shapiro AD, Maahs JA, Brewer AL: Clinical manifestations of a large kindred of patients with type 28 von Willebrand's disease (VWD). Haemophilia. 2(1):366a, 1996.

24. Warrier I, Ewenstein B, Koerper M, Shapiro A, Key N, DiMichele D, Miller A, Pasi J, Sommer S, Rivard G, Katz J, Lusher J: Factor IX inhibitors and anaphylaxis in hemophilia B (HB). Haemophilia. 2(1):159a, 1996.

25. White G, Shapiro A, Lusher J, Courter S, Tubridy K, and the Recombinant Factor IX Study Group: Recombinant factor IX in the treatment of hemorrhage in previously treated patients with hemophilia B. Haemophilia. 2(1):245a, 1996.

26. Ragni M, Shapiro A, White G, Pasi J, Laurian Y, Gencarella N, Quiles E, Courter S: Use of recombinant factor IX in six patients with hemophilia B undergoing surgery. Haemophilia. 2(1):420a, 1996.

27. Izumi T, Kirn SW, Quinn-Allen MA, Camp T, Shapiro AD, Macedo-Ribeiro S, Fuentes-Prior P, Bode W, Kane WH, Ortel TL: Fine mapping of inhibitory anti-factor V antibodies using factor V C2 domain mutants. Blood. 94(10); 11014a, 1999.

28. Shapiro A, Abshire T, Kisker T, Peerlinck K, Fernands A, Gencarella N: Recombinant factor IX (rFIX) in the treatment of previously untreated patients (PUP) with severe or moderately severe hemophilia B. Blood. 94(10); 1:1051a, 1999.

29. Manco-Johnson M, Nuss R, Abshire T, Richardson L, Shapiro A, Valentino L, for the Hemophilia Joint Preservation Study Group: Port infections in children with haemophilia. Haemophilia. 6(4);12a:275, 2000.

30. Ewenstein BM, Joist JH, Shapiro A, Hofstra T, Leissinger C, Seremetis S, Broder M, Mueller-Velten G, Schwartz BA for the Mononine Comparison Study Investigators: Factor IX pharmacokinetics of a plasma-derived and a recombinant factor IX concentrate (Mononine vs. BeneFIX) in previously treated subjects with moderate or severe haemophilia B. Haemophilia. 6(4);55a:365, 2000.

31. Shapiro A, Abshire T, Kisker CT, Peerlinck K, Fernands A and the Recombinant Factor IX Study Group: Recombinant factor IX (rFIX) treatment of previously untreated patients (PUPs) with severe or moderately severe haemophilia B. Haemophilia, 6(4);56a:366, 2000.

32. Shapiro AD, Danfield SM: Infectious complications of central venous access devices (CVAD) in children with haemophilia. Haemophilia. 6(4);1Ba27B, 2000.

33. Shapiro AD, Donfietd SM, Bray GL, Stehbens JA, Lynn HS, Cool VA, Hunsberger SL, Gomperts ED and the Academic Achievement in Children with Hemophilia Study Group: Academic achievement in children with severe haemophilia A. Haemophilia. 6(4);43a:427, 2000.

34. Parameswaran R, Shapiro A, Cox Gill J, Kessler C, HRS Registry Investigators. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Blood. 100(11)22a:69, 2002.

35. Shapiro AD. Infusion Data Electronic Analysis System: IDEAS; An advance in the care of individuals with blood disorders. National Hemophilia Foundation Abstract CR 16, Hemaware. 7(6):8, 2002.

36. Brown D, Shapiro A, Schuster V, Mets M. Treatment of Ligneous Conjuctivitis with Fresh Frozen Plasma. Blood. 102(11);1108:309a, 2003.

37. Ewenstein B, Collins P, Shapiro A, Tarantino M, Blanchette V, [Baxter Authors], and the rAHF-PFM Study Group. Global Evaluation of Advate rAHF-PFM, an Advanced Category Antihemophilic Factor Prepared Using a Plasma/Albumin-Free Method. Blood. 102(11);172:52a, 2003.

38. Saxena K, Gross T, Zhou B, Kraut E, Shapiro A, Hord J, Ruymann F, Yu CY. Immunogenetics of Hemophilia Inhibitors: A Multicenter Study. Blood. 102(11);2961:800a, 2003.

39. Tarantino M. Abshire T, Shapiro A, Collins P, Rogy S, Retzios A, Schroth P, Sensel M, Spotts G, Yi SE, Ewenstein B for the rAHF PFM Clinical Study Group. Global Clinical Evaluation of an rFVIII Prepared Using a

Plasma/Albumin-Free Method,ADVATE rAHF-PFM. PAS. 56:1629a, 2004.

40. Parameswaran R, Greist A, Miller-Rice L, Roberson C, Murry A, Sulkin M, Lynn H, Shapiro A. Framingham Score in Congenital Hemophilia Patients (HP) with Cardiovascular Disease (CVD). Blood. 106:320a, 2005.

41. Parameswaran R, Di Paola J, Miller-Rice L, Greist A, Shapiro A. High Dose Intranasa Desmopressin (DDAVP) Therapy in type 2M Von Willebrand Disease (vWD): A Prospective Open Label Trial. Blood. 106:17B3a, 2005.

42. Manco-Johnson M, Abshire T, Brown D, Buchanan G, Cohen A, DiMichele D, Hoots K, Leissinger C, McRedmond K, Nugent D, Shapiro A, Thomas G, Valentino L, and Riske B. Initial Results of a Randomized, Prospective Trial of Prophylaxis to Prevent Joint Disease in Young Children with Factor VIII (fVIII) Deficiency. Blood. 106:3a, 2005.

43. Di Paola J, Murray J, Lentz S, Montgomery R, Sayago C, Wang K, Burns T, Shapiro A. A Missense Mutation in Exon 28 (C4120T) of the Von Willebrand Factor Gene is the Cause for Von Willebrand Disease in a Large Amish Pedigree. J Thromb Haemost. 3{1):P1472, 2005.

44. Gelmont D, Hays T, Bomgaars L, Palascak J, Shapiro A, Geil J, Montgomery J, Fritsch S, Maritsch F, Pavlova B, Ehrlich HJ. A Phase 111111 Clinical Study for the Determination of the Efficacy and Safety of Protein C Concentrate in Subjects with Severe Congenital Protein C Deficiency – Interim Study Analysis. J Thromb Haemost. 3(1):P013B, 2005.

45. Negrier C, Shapiro A, Pabinger I, Berntorp E, Tarantino M, Retzios A, Fritsch S, Luu H, Ewenstein B. Clinical Efficacy and Safety Evaluation of ADVATE Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method (rAHF-PFM) During Surgical and Invasive Procedures. J Thromb Haemost. 3(1):POB29, 2005.

46. Liesner R, Shapiro A, Blanchette V, Hernandez F, Warrier I, Retzios A, Schroth P, Seltmann M, Spotts G, Ewenstein B. Efficacy, Safety and Pharmacokinetic Properties of ADVATE rAHF-PFM in Previously Treated Patients {PTPs) Less Than 6 years of Age. J Thromb Haemost. 3(1)P1B37, 2005.

47. Recht M, Shapiro A. Induction of Immune Tolerance Utilizing Third Generation Recombinant Factor VIII (Advate]: A Report of Two Cases. J Thromb Haemost. 3(1):P1442, 2005.

48. Tencer T, Shapiro A, Roberson C, Johnson KA. "Summary of the first year of a disease management program in patients with bleeding disordersn. Value in Health. 9(3)PHP9a, 2006.

49. Blanchette V, Chir V, Shapiro A, Liesner R, Hernandez F, Warrier I, Retzios A. ADVATE antihemophilic factor (recombinant), plasma/albumin free method (rAHF-PFM): pharmacokinetics, safety and efficacy in previously treated patients <6 years old. Haemophilia. 12(2):5a, 82, 2006.

50. Negrier C, Shapiro A, Bemtorp E, Pabinger I, Tarantino M, Gruppo R, Scharrer I, Retzios A, Fritsch S, Patrone L, Luu H, Ewenstein B. Clinical efficacy and safety of ADVATE antihemophillc factor (Recombinant), plasma/albumin-free method (rAHF-PFM) for perloperative management of hemostasis. Haemophilia. 12(2):05 P0104a, 2006.

51. Shapiro A, Abshire T, Hernandez F, Gruppo R, Tarantino M, Warrier I, Schroth P, Spotts G, Retzios A, Ewenstein B. Efficacy and safety of ADVATE rAHF-PFM for perioperative management of hemostasis in previously treated children with hemophilia A. Haemophilia. 12(2):05 P0119a, 2006.

52. DiPaola J, Rickard M, Murray J, Bums T, Wang K, Shapiro A. A Genome Wide Scan of a Large Amish Pedigree with von Willebrand Disease (vWD) Identified Regions of Linkage that Represent Potential Modifiers of von Willebrand Factor (vWF) Levels and Disease Variability. Blood. 108:176a, 2006.

53. Herbert S, Parameswaran A, Shapiro A, DiPaola J, Winay J, Roberson C, Greist A. A Prospective Comparison of Intranasal (I.N.) and Subcutaneous (S.C.) Desmopressin (DDAVP) Therapy in Type 2M van Willebrand Disease (vWD). Blood. 1081035a at 2006.

54. Mehta R, Simmons M, Heiman M, Shapiro A. Bleeding Complications and Pregnancies in an Established Plasminogen Activator Inhibitor, Type-1 (PAI-1) Deficient Population. Blood. 110:2147a, 2007.

55. Salter J, Hardesty B, Heiman M, Sulkin M, Shapiro A, Greist A. Bleeding Events and Factor IX Levels in Female Carriers from a Large Kindred of Hemophilia B. Blood. 1101150a, 2007.

56. Salter J, Shapiro A, Sulkin M, Heiman M, Greist A, Yoder P, Maahs J. A Tiered Management Program To Conserve Replacement Therapy Resources for a Rural Population of Women with Type 2M von Willebrand Disease during Labor and Delivery. Blood. 110:3961a, 2007.

57. Haberichter S, Christopherson P, Perry C, Lee A, Morateck P, Bellissimo D, Gill J, Abshire T, Di Paola J, Hoots WK, Leissinger C, Lusher J, Ragni M, Shapiro A, Montgomery R. The Prevalence of Reduced VWF Survival Phenotype (Type 1C VWD) in Type 1 Index Cases Recruited into the TS Zimmerman Program for the Molecular and Clinical Biology of VWD (ZPMCB - VWD). Blood. 110:2133a, 2007.

58. Di Paola J, Wagner K, Nixon B, Kline J, Shapiro A, Abbott 0, Burns T, Wang K. An Association Study of Candidate Modifier Genes in a Large Pedigree with Von Willebrand Disease. Blood. 110:2135a, 2007.

59. Miller C, Platt SJ, Abshire T, Brettler D, Brockenstedt P, DiPaola J, Massey G, Neff A, Shapiro A, Tarantino M, Wicklund 8, Creary M, Soucie JM. Experience with a Modified Nijmegen Bethesda Method for Measurement of Inhibitors in Hemophilia Patients: The CDC Inhibitor Surveillance Pilot Project. Blood. 110:1156a, 2007.

60. Creary M, Soucie J, Miller C, Hooper WC, Abshire T, Brettler 0, Pockenstedt P, DiPaola J, Massey G, Neff A, Shapiro A, Tarantino M, Wicklund B, DiMichele D, Hemophilia Treatment Centers, U.S. Inhibitor Pilot Project Participant Characteristics and Infusion Log Adherence. Blood. 110:1162a, 2007.

61. Bellissimo D, Christopherson P, Haberichter S, Flood V, GiU J, Friedman K, Abshire T, DiPaola J, Hoots WK, Leissinger C, Lusher J, Ragni M, Shapiro A, Montgomery R. Novel VWF Sequence Variations Identified in Normal Controls and Index Cases Enrolled fn the TS Zimmerman Prog am for the Molecular and Clinical Biology of VWD (ZPMCB-VWD). Blood. 110709a, 2007.

62. Flood V, Kautza B, Miller C, Branchford B, Gill J, Haberichter S, Morateck P, Christopherson P, Perry C, Friedman K, BelUssimo 0, Abshire T, Di Paola J, Hoots WK, Leissinger C, Lusher J, Ragni M, Shapiro A, Ullicrap D, Goodeve A, Peake I, Montgomery R. Common VWF Haplotypes in Normal African-Americans and Caucasians Recruited into the ZPMCB-VWD and Their Impact on VWF Laboratory Testing. Blood. 110714a, 2007.

63. Mahlangu J, Andreeva T, Macfarlane 0, Reding M, Walsh C, Ritchie B, Ewing N, Kessler C, Kempton C, Libby E, Zozulya N, Shapiro A, St-Louis J, Warrier I, Hoots WK, Gruppo R, Mueksch J. A Phase II Open-Label Study Evaluating Hemostatic Activity, Pharmacokinetics and Safety of Recombinant Porcine Factor VIII (081-1) in Hemophilia A Patients with Alloan Hbody Inhibitors Directed Against Human FVIII. Blood. 110:783a, 2007.

64. Shapiro AD, Gill JC, Di Paola J, Bergman G. Low Risk from High Levels of Coagulation Factors in VWD Subjects Undergoing Surgery? Haemophilia. 14(s2)18 P0;26a, 115, 2008.

65. Valentino L, Recht M, DiPaola J, Shapiro A, Ppe S, Ewing N, Urge J, Bullock T, Simmons M, Pipe R, Dueguzman C. Experience with a third generation recombinant factor VIH concentrate (Advate_) for immune tolerance induction in patients with hemophilia A. Haemophilia. 14(s2)03 P0;44a, 16, 2008.

66. Mahlangu J, Andreeva T, MacFarlane 0, Reding M, Walsh C, Ewing N, Kessler M, Kempton C, Mathew P, Plyushch 0, Shapiro A, St.-Louis J, Warrier I, Hoots K, Gruppo R on behalf of the Octagen Corporation. A phase II open-label study evaluating the hemostatic activity, pharmacokinetics and safety of recombinant porcine factor VIII (OBI-1) in hemophilia A patients with inhibitors directed against human FVIII. Haemophilia. 14(s2)03 P0;43a;15, 2008.

67. Aschman 0, Shapiro A, Lusher J. American Thrombosis and Hemostasis Network: expanding capacity for electronic data management across US affiliates. Haemophilia. 14(s2)05 P0;08a;31, 2008.

66. Sharathkumar A, Trawinski B, Soucie M, Greist A, Haddix C, Shapiro A. Cardiovascular Disease in Patients with Hemophilia: Single Centre Experience. Blood. 112:2272a, 2006.

69. Miller C, Hooper C, Abshire T, Bockenstedt P, Brettler 0, DiPaola J, Massey G, Neff A, Shapiro A, Tarantino M, Wicklund B, Manco-Johnson M, Dunn A, Knoll C, Creary M, Benson J, Ellingsen 0, Driggers J, Soucie M. Factor VIII and Factor IX Mutation Analysis in 600 U.S. Hemophilia Patients: Correlation of Mutation Type with History of Inhibitor. Blood. 112:1017a, 2008.

70. Duncan N, Roberson C, Shapiro A. Administration and evaluation of a Hemophilia Treatment Center-administered disease management program for individuals with bleeding disorders insured by Indiana's high-risk insurance pool. American Public Health Association oral presentation. 2006.

71. Astermark J, Schwarz M, Danfield S, DiMichele D, Ewenstein B, Gomperts E, Nelson G, Oldenburg J, Shapiro A, Spotts G, Winkler C, Berntrop E. Genetic Factors Associated with Inhibitor Development in Hemophilia A: Initial Results From the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. Blood. 114:217, 2009.

72. Young G, Shapiro A, Valentino L, Kessler C, Cooper D. Diary Observational Study in Hemophilia (DOSE): Evaluation of Enrolled Population and Overall Diary Data Capture in Congenital Hemophilia Patients with Alloantibody Inhibitors. Blood. 114:3464, 2009.

73. Soucie JM, Creary M, Abshire T, Brattier 0, Bockenstedt PL, DiPaola J, Massey G, Neff AT, Shapiro AD, Tarantino M, Wicklund BM, Manco-Johnson MJ, Dunn AL, Knoll C, Platt SJ, Driggers J, Ellingsen D, Benson J, Hooper C, Miller CH. Inhibitor surveillance and mutation analysis in hemophilia B patients. J Thromb Haemost. 7(52):PP-WE-613, 2009.

74. Di Paola J, Abbott D, Wang K, Hinckley J, Murray J, Nixon B, Burns TL, Shapiro A. Quantitative trait loci (QTL) for von Willebrand factor (VWF) levels in a large pedigree with von Willebrand disease (VWD). J Thromb Haemost. 7(S2):PP-WE-636, 2009.

75. Sharathkumar AA, Soucie M, Trawinski B, Griest A, Shapiro A. Cardiovascular disease in patients with hemophilia B. J Thromb Haemost. 7(S2):PP-M0-522, 2009.

76. Miller CH, Hooper C, Benson J, Ellingsen D, Driggers J, Abshire TC, Bockenstedt PL, Brettler DB, Di Paola J, Massey G, Neff AT, Shapiro AD, Tarantino M, Wicklund BM, Manco-Johnson MJ, Dunn AL, Knoll C, Creary M, Soucie JM. Novel factor VIII mutations in US hemophilia patients: relationship to ethnicity and inhibitor history. J Thromb Haemost. 7(S2)PP-M0-596, 2009.

77. Sood SL, James AH, Bolgiano D, Ragni MV, Shapiro AD, Shihong I, Vega R, Witmer C, Konkle BA. Pregnancy in Type 1 Von Willebrand Disease: A Prospective Study of VWF Levels and Risk Factors for Bleeding. Blood. 116: 1410, 2010.

78. Suiter T, Laffan M, Mannucci P, Kempton CL, Romond EH, Shapiro AD, Birschmann I, Gill JC, Ragni MV, Turecek P, Ewenstein BM, and rhVWF Study Team Baxter BioScience.

Recombinant Human Von Willebrand Factor (rhVWF): First-In-Human Study Evaluating Pharmacokinetics, Demonstrating Safety and Tolerability In Type 3 Von Willebrand Disease. Blood. 116: 237, 2010.

79. Hinckley J, Wang K, Burns T, Shapiro AD, Di Paola JA. Quantitative Trait Locus (QTL) Linkage Analysis of a Large Pedigree with Von Willebrand Disease Identifies Novel Modifier Loci of Von Willebrand Factor Levels and Confirms Some Previously Reported Modifier Loci. Blood. 116: 240, 2010.

80. Shapiro AD, Neufeld EJ, Cooper DL. Safety of Exposure to Recombinant Activated FVII (rFVIIa) Doses In Patients with Hemophilia and Inhibitors (CHwI) to Factors VIII or IX. Blood. 116: 3675, 2010.

81. Berntorp E, Waters J, Astermark S, Danfield S, Shapiro A. The International Factor IX Treament Network survey. Haemophilia. 16(S4): 46, 2010.

82. Zhou ZY, Johnson K, Riske B, Ullman M, Baker J, Koerper M, Forsberg A, Miller B, Shapiro A, Huszti H. Heath care utilization and cost in persons with factor VIII deficiency: results of the HUGS VA study. Haemophilia. 16(S4): 59, 2010.

83. Gruppo R, Kessler C, Neufeld E, Shapiro A, Cooper D, Carr Jr M. A comparison of prescribed and actual recombinant factor VIIa (rFVIIa) dosing in pediatric versus adult patients with congenital hemophilia with inhibitors (CHwI): analysis of the dosing observational study in hemophilia (DOSE). Haemophilia. 16(S4): 73, 2010.

84. Duncan N, Shapiro A, Ye X, Epstein J, Luo M. Adherence to therapy among hemophilia patients in the US. Haemophilia. 16(S4): 137, 2010.

85. Shapiro AD, Ragni M, Valentino L, Key N, Josephson N, Powell J, Cheng G, Turbridy KL, Peters R. Dumont J, Luk A, Hallen B, Gozzi P, Bitonti A, Pierce GF. Safety and prolonged biological activity following a single administration of a recombinant molecular fusion of native human coagulation factor IX and the Fc region of immunoglobulin G (IgG) (rFIXFc) to subjects with hemophilia B. Haemophilia. 16(S4): 30, 2010.

86. Shapiro AD, Neufeld EJ, Blanchette VS, Chambost H, Salaj P, Gut RZ, Cooper DL. Safety of Recombinant Activated Factor VII (rFVIIa) Exposure in Patients with Congenital Hemophilia with Inhibitors (CHwI) to Factors VIII or IX. J Thromb Haemost. 9(S2): P-TU-518, 2011.

87. Martinowitz U, Shapiro AD, Quon DV, Escobar MA, Kempton CL, Collins P, Chowdary P, Makris M. Mannucci PM, Morfini M, Valentino LA, Gomperts ED, Lee M. Pharmacokinetic Behavior of 181001, An Investigational Recombinant Factor IX, in Patients with Hemophilia B: Repeat Pharmacokinetic Study and Subgroup Analysis. Blood. 118: 2267, 2011.

BB. Suiter TM, Mannucci PM, Kempton CL, Laffan M, Remand EH, Shapiro AD, Birschmann I, Ragni MV, Gill JC, Yee TT, Klamroth R, Horling FM, Reipert BM, Turecek PL, Varadi K, Chapman M, Engl W, Wong WY, Ewenstein BM, rhVWF Study Team. Detection of Non Inhibitory Binding Antibodies to Von Willebrand Factor Affecting the Clearance of VWF:Ag in Von Willebrand Disease. Blood. 118: 2275, 2011.

89. Shapiro AD, Neufeld EJ, Blanchette VS, Chambost H, Salaj P, Gut RZ, Cooper DL. Safety of Recombinant Activated Factor VII (rFVIIa) in Patients with Congenital Hemophilia with Inhibitors: Overall Dose Exposure and Intervals Following >240 Meg/Kg Doses Across Trial, Registry and Diary Studies. Blood. 118: 3316, 2011.

90. Greist A, Shapiro A, Kruse-Jarres R, St Louis J, Smith H, Gomperts E. Efficacy and safety of B-domain deleted recombinant porcine factor VIII (081-1) in the treatment of acquired hemophilia A: interim results. Haemophilia. 18 (S3): 1, 2012.

91. Shapiro,A, Khair K, Ghandehari H,Song C, Leony-Lasso I, Schoenig-Desing C, Spotts G. Prospective Advate Immune Tolerance Induction Registry (PAIR) in Hemophilia A Patients with Inhibitors: Interim Report. Haemophilia 18(S3):95, 2012.

92. Chambost H, Rafowicz A, Guillaume Y, Liesner R, Nolan B, Shima M, Shapiro A. Perinatal practices in the context of hemophilia carrier: Exert opinion from an international pediatric panel. Haemophilia 18(S3):148, 2012.

93. Suiter TM, Mannucci PM, Kempton CL, Laffan M, Romond EH, Shapiro AD, Birschmann I, Ragni MV, Gill JC, Klamroth R, Reipert BM, Turecek PL, Varadi K, Chapman M, Engl W, Ewenstein BM, and RHVWF Study Team. Detection of non-inhibitory binding antibodies to von Willebrand factor affecting the clearance of VWF:Ag in von Willebrand disease. Haemophilia 18(S3):200, 2012.

94. St. Louis J, Kruse-Jarres R, Greist A, Shapiro AD, Smith H, Drebes AB, Lozier JN, Gomperts ED. Recombinant B-Domain Deleted Porcine Factor VIII (OBI-1) Safety and Efficacy in the Treatment of Acquired Hemophilia A: Interim Results. Blood. Nov. 120:2224, 2012.

95. Gomperts ED, Apte S, Chaudhuri U, John JM, Ramanan V, Liesner R, Shapiro AD, Mills BJ, Lee M. 181001, an Investigational Recombinant Factor IX, Pharmacokinetics in Pediatric Patients with Hemophilia B. Blood. Nov. 120(22)225, 2012.

96. Mahlangu J, Powell J, Ragni M, Chowdary P, Josephson N, Pabingerfasching I, Hanabusa H, Gupta N, Kulkarni, R, Fogarty P, Perry D, Shapiro A, et.al. Phase 3 clinicalstudy of recombinant FC fusion factor FVIII (RFVIIIFC) demonstrated safety, efficacy, and improved pharmacokinetics (A-LONG). Haemophilia. 19(S2):70, 2012.

97. Mahlangu J, Powell J, Ragni M, Chowdary P, Josephson N, Pabinger I, Hanabusa H, Gupta N, Kulkarni R, Fogarty P, Perry D, Shapiro AD, et al. A-Long: results from a Phase 3 study of safety, efficacy, and pharmacokinetics of long-lasting recombinant factor VIII Fe fusion protein (rFVIIIFc). ABSTRACTS OF THE XXIV CONGRESS OF THE INTERNATIONAL SOCIETY ON THROMBOSIS AND HAEMOSTASIS. J Thromb Haemost 11 (S2):168. 2013.

98. Neelakantan S, Li S, Powell J, Josephson N, Pasi J, Perry D, Shapiro AD, et al. Population pharmacokinetic analysis of long-lasting factor VIII Fe fusion protein (fFVIIIFc) in patients with severe haemophilia A. ABSTRACTS OF THE XXIV CONGRESS OF THE INTERNATIONAL SOCIETY ON THROMBOSIS AND HAEMOSTASIS. J Thromb Haemost 11 (S2):354. 2013.

99. Li S, Diao L, Powell J, Shapiro AD, et al. Clinical implications of population pharmacokinetics of rFIXFc in routine prophylaxis, control of bleeding and perioperative management for haemophilia B patients. ABSTRACTS OF THE XXIV CONGRESS OF THE INTERNATIONAL SOCIETY ON THROMBOSIS AND HAEMOSTASIS. J Thromb Haemost 11 (S2):358. 2013.

100. Mahlangu J, Powell J, Josephson N, Klamroth R, Parra Lopez R, Martini M, Oldenburg J, Pasi J, Perry D, Ragni M, Shapiro AD, et al. Long-lasting recombinant factor VIIIFe fusion (rFVIIIFc) for perioperative management of subjects with haemophilia A in the phase 3 A-Long study. ABSTRACTS OF THE XXIV CONGRESS OF THE INTERNATIONAL SOCIETY ON THROMBOSIS AND HAEMOSTASIS. J Thromb Haemost 11 (S2):459. 2013.

101. Shapiro AD, Romanov V, Silvati-Fidell L, Wong WY2d Schoenig-Desing C. Integrated analysis of safety data from 12 clinical interventional studies of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) in persons with hemophilia A (HemoA). ABSTRACTS OF THE XXIV CONGRESS OF THE INTERNATIONAL SOCIETY ON THROMBOSIS AND HAEMOSTASIS. J Thromb Haemost 11 (52):532. 2013.

102. Shapiro AD, Khair K, Teitel J, Leony-Lasso I, Matovinovic E, Schoenig-Oiesing CK, Spotts G. Ongoking prospective rAHF-PFM immune tolerance induction registry (PAR): success rates continue to support published literature. ABSTRACTS OF THE XXIV CONGRESS OF THE INTERNATIONAL SOCIETY ON THROMBOSIS AND HAEMOSTASIS. J Thromb Haemost 11 (S2): 534. 2013.

103. Lock J, Raat H, Duncan NA, Shapiro AD, et al. Adherence to hemophilia treatment in the Dutch pediatric population; reliability and validity of the VEAITAS-Pro questionnaire. ABSTRACTS OF THE XXIV CONGRESS OF THE INTERNATIONAL SOCIETY ON THROMBOSIS AND HAEMOSTASIS. J Thromb Haemost 11 (S2): 801. 2013.

104. Aagni M, Josephson N, Mahlangu J, Pasi J, Perry D, Powell J, Shapiro AD, et al. Treatment of bleeding episodes in subjects with haemophilia A with long-lasting recombinant Factor VIII Fe fusion protein (rFVIIIFc) in the Phase 3 A-LONG study. ABSTRACTS OF THE XXIV CONGRESS OF THE INTERNATIONAL SOCIETY ON THROMBOSIS AND HAEMOSTASIS. J Thromb Haemost 11 (52): 928. 2013.

105. Quon DV, Shapiro AD, Santagostino E, et al. Impact of rAHF-PFM prophylactic treatment on annual bleeding rate and health-related quality of life of adults with severe hemophilia A. ABSTRACTS OF THE XXIV CONGRESS OF THE INTERNATIONAL SOCIETY ON THROMBOSIS AND HAEMOSTASIS. J Thromb Haemost 11 (S2): 1081. 2013.

106. Xavier F, Maahs J, Hallett AL, Nakar C, Rampersad A, Gupta S, Shapiro AD. Successful anticoagulation with concomitant factor VIII replacement in a severe haemophilia A patient suffering a life threatening thrombotic event. ABSTRACTS OF THE XXIV CONGRESS OF THE INTERNATIONAL SOCIETY ON THROMBOSIS AND HAEMOSTASIS. J Thromb Haemost 11 (52): 1086. 2013.

107. Quon D, Mahlangu J, Shapiro AD, Pasi J, Zhu Y, Pierce GF, Li L, Allen G. Predicting FVIII Activity in Patients Who Use Recombinant FVIII Fe Fusion Protein for Prophylaxis and Treatment of Bleeding Episodes. Blood. 124: 1522. 2014.

108. Sood S, Cheng D, Shapiro AD, Kessler CM, Key NS, et al. A Cross-Sectional Analysis of Cardiovascular Disease in the Hemophilia Population. Blood. 124: 2836. 2014.

109. Peyvand F, Menegatti M, Palla R, Siboni SM, Heiman M, Shapiro AD, et al. Prospective Data Collection on Patients with Fibrinogen and Factor XIII Deficiencies: Preliminary Results of the PRO-ABDO Project. Blood. 124: 2838. 2014.

110. Oldenberg J, Shapiro A, Ragni M, Kulkarni R, Srivatava A, Quon D, et al. Switching to treatment with recombinant factor VIII Fe fusion protein: extended dosing interval yields low bleeding rates with comparable factor consumption and is correlated with a von Willebrand Factor levels. Haemophillia. 20(S3): 187. 2014.

111. Negrier C, Powell J, Shapiro A, Aagni M, Windyga J, et al. Recombinant factor IX Fe fusion protein dosing conversion: extended-interval dosing yields low bleeding rates and a reduction in factor consumption. Haemophillia. 20(S3): 187. 2014.

112. Manco-Johnson MJ, Manco-Johnson ML, Blades T, Funk S, Lane AL, Recht M, Shapiro AD, et. al. What is the cost of delaying prophylaxis until the school years? Results from the Joint Outcome Study Continuation Project. Haemophillia. 20(S3): 99. 2014.

113. Novack A, St-Louis J, Greist A, Shapiro A, Smith H, Chowdary P, Drebes A, Lozier J, Bourgeois C, MoM, Farin H. OR028; Perioperative management of bleeds with recombinant porcine FVIII in patients with acquired hemophilia A. J Thromb Haemost 13 (S2): 104. 2015.

114. Jackson S, Perry D, Quon D, Chowdary P, Shapiro A, Pabinger I, Santagostino E, U X, Glazebrook DV, Allen GA. P0235-MON; Safety and efficacy of recombinant factor VIII FC fusion protein (RFVIIIFC) for the

prevention and treatment of bleeding in previously-treated adult and adolescent subjects with hemophilia A: interim analysis of the aspire study. J Thromb Haemost 13 (S2):346. 2015.

115. Wang M, Neff A, Shapiro A, Kulkarni R, Reding M, Kuriakose P, Kessler C, Witkop M, Kempton C Cooper O. P0277-MON; Reliability of patient-reported outcome (PRO) instruments in US adult people with hemophilia (pwh): the pain functional impairment and quality of life (PFIQ) study. J Thromb Haemost 13 (S2):363. 2015.

116. Peyvandi F, Menegatti M, Palla R, Siboni SM, Boscarino M. Pergantou H, Platokouki H, Lachmann B, Halimeh S, van Lent M, Brans P, Lares-van Gorkom B, Fatima N, Borhany M, Ylmaz A, Williamson A, Shapiro A. et al. P0522-MON; Fibrinogen deficiency: preliminary results of the PAORBDD project. J Thromb Haemost 13 (S2):443. 2015.

117. Shapiro A, Khair K, Teitel! J, Leony-Lasso I, Steinitz K, Gringeri A and Spotts G. P0286-WEO; Immune tolerance induction experience with advate: final results of an international prospective ITI registry (PAIR). J Thromb Haemost 13 (S2):855. 2015.

118. Peyvandi F, Palla R, Menegatti M, Siboni SM, Boscarino M, et.al. P0521-WED; Factor XIII deficiency: preliminary results of the PRO-RBDD project. J Thromb Haemost 13 (S2):940. 2015.

119. Hardesty 8, Plum S, Thibaudeau K, Lee M, Shapiro AD. Pharmacokinetics of Intravenous Infusion of Glu-Plasminogen Concentrate in Patients with Hypoplasminogenemia. Blood. 126(23)3498. 2015.

120. Shapiro AD, Perry DJ, Baker RI, Tsao E, Mei B. Analysis of Target Joint Bleeding with Prophylactic Use of Recombinant Factor IX FC Fusion Protein in Patients with Severe Hemophilia B. Blood. 126(23)2294. 2015.

121. Quon DV, Klamroth R, Kulkarni R, Shapiro AD, et. al. Low Bleeding Rates with Increase or Maintenance of Physical Activity in Patients Treated with Recombinant Factor VIII Fe Fusion Protein (rFVIIIFc) in the A-LONG and Kids A-LONG Studies. Blood. 126(23):3543. 2015.

122. Kulkarni R, Shapiro AD, Windyga J, Ragni MV, et. al. Low Bleeding Rates with Increase or Maintenance of Physical Activity in Patients Treated with Recombinant Factor IX Fe Fusion Protein (rFIXFc) in the 8-LONG and Kids 8-LONG Studies. Blood. 126(23):2307. 2015.

123. Nakar CT, Caputo R, Price FW, et. al. Safety & Efficacy of Human Plasma Derived Plasminogen Ophthalmic Drops for Treatment of Ligneous Conjunctivitis: Report of Phase 2/3 Clinical Trial. Blood. 126(23) 2288. 2015.

124. Mahlangu J, Shapiro AD, Pasi KJ, et. al. Extended-Interval Prophylaxis with rFIXFc in Adults and Adolescents with Hemophilia B: Interim Results of the B-YOND Extension Study. Blood. 126(23):1088. 2015.

125. Warren BB, Jacobsen L, Villaobos-Menuey E, Abshire TC, Shapiro AD, et. al. Non-Factor VIII Coagulation Proteins Fail to Predict Joint Outcome in Severe Hemophilia A. Blood. 126(23):2289. 2015.

126. Sood S, Chenj D, Raagni MV, Kessler CM, et. al. A Cross-Sectional Analysis of Cardiovascular Disease in the Hemophilia Population. Blood. 126(23) :761. 2015.

127. Mahlangu J, Ragni MV, Shapiro AD, et al. Long-term safety and efficacy of recombinant factor IX Fe fusion protein (rFIXFc) in adults/adolescents with hemophilia 8: ongitudinal analysis of B-LONG and B-YOND. Haemophilia. 22(Suppl.4):47. 2016.

128. Quon DV, Young G, Ragni MV, Konkle BA, Kulkarni R, Shapiro AD, et. al. Long-term efficacy of recombinant factor VIII Fe fusion protein (rFVIIIFc) in adults/adolescents with severe hemophilia A: United States subgroup analysis of A-LONG and ASPIRE. Haemophilia. 22(Suppl.4): 50. 2016.

129. Shapiro AD, Srivastava A, Ragni MV, et al. Longitudinal analysis of annualized bleeding rates among adults/adolescents receiving weekly prophylaxis with rFVIIIFc in A-LONG and ASPIRE. Haemophilia. 22(Suppl.4):108. 2016.

Book or Book Chapters:

1. Shapiro AD: Hemophilia. In Ambulatory Pediatrics, 4th edition. Green and Haggerty; W.8. Saunders Company. 1990.

2. Shapiro AD: Purpura. In Ambulatory Pediatrics, 4th edition. Green and Haggerty; W.8. Saunders Company. 1990.

3. Shapiro AD: Bleeding and clotting disorders. In Common Problems in Pediatric Surgery. Grosfeld; Mosby Yearbook. 1991.

4. Shapiro AD: Hemophilia B (Factor IX Deficiency). Jn Disorders of Hemostasis & Thrombosis, 2nd edition. Goodnight and Hathaway; McGraw-Hill, 2001.

5. Shapiro AD: Coagulation Factor Concentrates. In Disorders of Hemostasis & Thrombosis, 2nd edition. Goodnight and Hathaway; McGraw-Hill, 2001.

6. Sanders BJ, Shapiro AD, Hock RA, Weddell JA, Belcher CE, McDonald RE, Avery DR, Dean JA, eds. Management of the Medically Compromised Patient: Hematological Disorders, Cancer, Hepatitis and AIDS. In: Dentistry for the Child and Adolescent. 8th ed. St. Louis, MO: Mosby. 557-579, 2004.

7. Shapiro A, Parameswaran R. Miscellaneous rare bleeding disorders. In: Textbook of Haemophilia. Blackwell Publishing, Chapter 58, 338-344, 2004.

8. Sharathkumar A, Shapiro A. Neurologic Aspects of Hemophilia. A Monograph for MedInk Neurology. Oct., 2008.

9. Sharathkumar A, Shapiro AD. Platelet function disorders. TOH Monograph. World Federation of Hemophilia 4(19):1-22, 2008.

10. Reversal of anticoagulation: Guidelines for physicians. Booklet written for the National Anticoagulation Safety Initiative. 2010.

11. Shapiro AD, Young G. Bleeding Disorders. In ASH Self-Assessment Program. 4th edition. American Society of Hematology, Chapter 8. 2010.

12. Tandra A, Shapiro AD. Treatment of inhibitors in hemophilia 8. In: Textbook of Haemophilia. 2nd edition. Blackwell Publishing, Chapter 15. 2010.

13. Sharathkumar A, Shapiro AD. Miscellaneous bleeding disorders. In: Textbook of Haemophilia. 2nd edition. Blackwell Publishing, Chapter 56. 2010.

14. OiPaofa, J, Shapiro, AD. Bleeding Disorders. In ASH Self-Assessment Program. 5th edition. American Society of Hematology, Chapter 9. 2013.